RA Capital Management Research
Investment Thesis
RA Capital Management is an evidence-based, multi-stage investment manager dedicated to healthcare, life sciences, and planetary health. Founded in 2004 by Peter Kolchinsky, PhD, the firm's core thesis is that deep scientific diligence—grounded in comprehensive disease and technology landscape research—can systematically identify breakthrough innovations and support them from inception through commercialization and beyond. RA Capital pairs scientific rigor with multi-stage capital flexibility and hands-on operational insight. Unlike many biotech-focused funds that concentrate at one stage, RA Capital deliberately invests across the full innovation lifecycle: from founding NewCos through seed, venture, crossover, IPO, and public markets, as well as structured debt and credit solutions for commercial-stage companies.
Sector Focus
RA Capital invests in two primary domains:
-
Healthcare & Life Sciences: Therapeutics (biotech, pharma, gene therapy, cell therapy, radiopharmaceuticals, RNA medicines), diagnostics, medical devices, health tech, and healthcare services. The firm has deep expertise across oncology, immunology/autoimmune diseases, rare genetic diseases, neurology, cardiovascular, endocrinology, and infectious disease.
-
Planetary Health: Capital-efficient companies addressing resource availability, energy innovation, and industrial productivity. Focus verticals include critical minerals, energy, manufacturing, agriculture, and environmental services. Planetary Health investments must have a near-term path to profitability without relying on subsidies or policy support.
Stage Focus
RA Capital is explicitly multi-stage and invests at every point in the company lifecycle:
- NewCo creation / incubation: Through Raven, RA Capital's internal healthcare incubator, the firm founds companies from scratch when biomedical white spaces exist
- Pre-Seed / Seed: First institutional money, may invest as early as proof-of-concept or even just an idea
- Series A, B, C: Traditional venture rounds with deep diligence support from TechAtlas
- Crossover: Lead or anchor crossover financings ahead of IPO
- IPO and public markets: Anchor IPOs and maintain public equity positions as stories mature
- Structured Capital: Flexible credit, debt, royalty, and hybrid solutions for commercial-stage companies
Check Size
RA Capital has no rigid check size floor or ceiling. The firm has invested under $1M in early seed rounds and as much as $200M in a single financing. Check size is determined by the risk/return profile of the opportunity and the fund's conviction level. The firm focuses on opportunities where the return can be meaningful to the fund, regardless of absolute dollar amount. Typical venture rounds likely range from $5M to $50M+, with crossover and public positions potentially larger.
Lead Tendency
RA Capital can lead, co-lead, or participate in rounds depending on what makes sense for the company. When they lead or co-lead, they shape the syndicate, articulate the investment thesis, and manage round dynamics. When participating, they are constructive partners who share diligence and help fill out rounds. They prefer working with investors who take larger positions (>$10M) given alignment with long-term value creation.
Recent Activity
RA Capital has been highly active through 2024-2026 with numerous exits and new fund launches:
- 2025: $650M+ deployed into private financings across the year
- July 2025: Closed inaugural $120M Planetary Health Fund (final close)
- September 2025: Provided $100M initial (up to $250M) structured loan facility to ARS Pharmaceuticals alongside OMERS Life Sciences for commercialization of neffy (needle-free epinephrine nasal spray)
- 2025 exits: Cidara (Merck), Halda (J&J), Elektrofi (Halozyme), Merus (Genmab), Metsera (Pfizer), 89bio (Roche), Interius Bio (Kite/Gilead), Hillevax (Xoma Royalty), Capstan (AbbVie), Verve (Eli Lilly), Inozyme (BioMarin), iDRx (GSK)
- 2024 exits: Aliada Therapeutics (AbbVie, $1.4B); Aiolos Bio (GSK); Jnana (Otsuka); InhibRx (Sanofi); ProfoundBio (Genmab); Shockwave (J&J)
- September 2024: Launched Structured Capital Solutions strategy led by Jeremy Lack and Adam Kaye
Portfolio Highlights
RA Capital's portfolio of 247+ companies spans some of the most notable names in biotech and life sciences:
- Notable IPOs/public companies: Moderna, Natera, Arvinas, Blueprint Medicines, Ascendis Pharma, Vaxcyte, BioAge Labs, Apogee Therapeutics, Crinetics, C4 Therapeutics, Stoke Therapeutics, Wave Life Sciences, Freenome, Biohaven, Dyne Therapeutics, Element Biosciences, Seres Therapeutics
- Notable exits (acquired): Aliada Therapeutics ($1.4B to AbbVie), Cidara (Merck), Ajax Therapeutics (Eli Lilly), Capstan (AbbVie), Verve (Eli Lilly), Merus (Genmab), Metsera (Pfizer), 89bio (Roche), Shockwave (J&J), iDRx (GSK), Juno (Celgene), AveXis (Novartis), Carmot Therapeutics (Roche), Global Blood Therapeutics (Pfizer), Day One (Servier)
- Raven-incubated companies (built from scratch): Aliada Therapeutics, Mariana (acquired by Novartis), Aerovate/Jade Bio, Climb Bio
- Planetary Health portfolio: Sortera Technologies (metal recycling AI), Koloma (geologic hydrogen), AM Batteries (dry electrode Li-ion), Bia (LatAm smart meter electricity), Optivolt (solar electronics), Aperion Labs (ocean monitoring), Avalanche (compact fusion), Reframe Systems (robotic modular homes), Pluton Bio (soil microbes)
Team
- Peter Kolchinsky, PhD — Founder and Managing Partner; PhD in virology from Harvard; author of "The Great American Drug Deal"; CNBC contributor; known for healthcare policy advocacy
- Rajeev Shah — Managing Partner; has collaborated with Kolchinsky for over two decades building the firm's investment culture
- Kyle Teamey — Managing Partner, Planetary Health; previously Partner at Breakthrough Energy Ventures; investment principal at In-Q-Tel; CEO/Co-Founder of Liquid Light (acquired by Avantium)
- Brigid O'Brien, PhD — Managing Partner, Planetary Health; formerly Managing Director at In-Q-Tel Australia and Head of Venture Investments at BHP (world's largest mining company by market cap)
- Zach Scheiner, PhD — Partner, Healthcare
- Jake Simson, PhD — Partner, Healthcare
- Matt Hammond, PhD, MBA — Partner, Healthcare
- Derek DiRocco, PhD — Partner, Healthcare
- Josh Resnick, MD — Partner, Healthcare
- Jeremy Lack, DPhil — Partner, Structured Capital; formerly Athyrium Capital Management
- Adam Kaye — Senior Managing Director and Partner, Structured Capital; formerly Sixth Street
The investment team is notably scientific: many partners hold PhDs or MDs and have deep domain expertise in specific therapeutic areas. The team of 200+ includes a large internal research division (TechAtlas) with dedicated associates mapping disease landscapes.
Decision Process
RA Capital uses a partnership/investment committee process. The large team with scientific depth means diligence is thorough and multi-layered: TechAtlas research maps the landscape before deals are done, and the investment and research teams jointly originate conviction. They will sign CDAs when interested in learning non-public information and can provide CDA templates. They work across US and global innovation hubs.
Founder Preferences
RA Capital backs founders from seed to public markets, including pre-seed founders whose company is just an idea. They judge investability not by company maturity but by how validated the concept is and what time/capital is needed to reach proof-of-concept. They explicitly state they will invest in a company "three years from IND." For Planetary Health, they prefer companies with product-market fit and a near-term path to profitability. They are comfortable being the first institutional investor and helping shape company strategy.
Geographic Focus
Primarily United States, headquartered in Boston with offices in other major innovation hubs. They invest globally—portfolio includes companies in the UK, Netherlands, Israel, LatAm, and Asia. Their planetary health mandate is explicitly global, with experience navigating international complex investments.
Proprietary Platforms
- TechAtlas: Internal knowledge engine; team of MDs and PhDs has diligenced 9,000+ companies and thousands of molecules; maps disease and technology landscapes to identify opportunities and risks; powers all investment decisions
- Raven: Healthcare incubator; builds companies from scratch to address biomedical white spaces; incubated companies include Aliada, Mariana, Aerovate/Jade Bio
- Blackbird: Clinical development accelerator for portfolio companies
- Gateway: Board tools for portfolio company management
- Structured Capital: Launched 2024; offers equity, credit, debt, royalty, and hybrid financing solutions for commercial-stage companies
- RA University: Free online courses for the broader biotech community